This is very disappointing news out of Allon Therapeutics, a Canadian company paying for a trial of davunetide in progressive supranuclear palsy (PSP). I’ll see if I can find out more details. UCSF was the lead investigator of the study.
Allon announces PSP clinical trial results
December 18, 2012
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that its pivotal clinical trial evaluating its lead product candidate davunetide as a treatment for progressive supranuclear palsy (PSP) failed to demonstrate efficacy in this population.
The study had co-primary outcome measures: the Progressive Supranuclear Palsy Rating Scale (PSPRS), and the Schwab and England Activities of Daily Living (SEADL). Data analysis failed to detect an effect on either the PSPRS or the SEADL.
The study also examined a series of secondary and exploratory endpoints. There was no evidence of a drug effect on these secondary or exploratory endpoints in the pre-specified analysis. The Company will undertake further analysis to determine if there is any evidence of an effect or explanation for the absence of an effect.